Isotopen Technologien München

Isotopen Technologien München develops and manufactures targeted radiopharmaceuticals for the diagnosis and treatment of cancer. The company specializes in the production of medical radioisotopes and radiopharmaceuticals used primarily in precision oncology. Its pipeline includes diagnostic and therapeutic agents based on a theranostic approach, which combines imaging and therapy using isotopes of the same chemical element. Isotopen Technologien München operates a GMP-certified manufacturing facility and maintains a proprietary generator technology for producing specific medical isotopes. The company also supports clinical research and supplies radioisotopes for academic and pharmaceutical partners involved in nuclear medicine and oncology trials. It collaborates with hospitals and research institutions to facilitate the integration of targeted radiopharmaceuticals into clinical practice. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine cancers or bone metastases. ITM’s main objectives, together with its scientific, medical, and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.

Domain

itm-radiopharma.com

Country

Germany

Industry

Biopharma

Employees

501-1000

Last Funding

$262.5M

Founded

2003